Primary Endpoints In Two Pivotal Studies
30/04/2025 13:36
April 30 (Reuters) - Lantheus Holdings Inc LNTH.O: LANTHEUS ANNOUNCES ALZHEIMER’S DISEASE RADIODIAGNOSTIC MK-6240 MEETS CO-PRIMARY ENDPOINTS IN TWO PIVOTAL STUDIES LANTHEUS HOLDINGS INC - NDA SUBMISSION FOR MK-6240 EXPECTED IN Q3 2025 Source text: ID:nGNXbKRdgR Further company coverage: LNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsStreet View: Lantheus' tumor kit setback seen as temporary, with growth catalysts still ahead
Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say